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The majority of liver related morbidity and mortality in NAFLD is secondary to the complications of advanced fibrosis and fibrosis stage predicts clinical outcome. [5] [6] [7] This offers valuable prognostic information to patients and their clinicians. In addition to fibrosis staging, distinguishing between simple steatosis and NASH is highly relevant for risk stratification in clinical practice and the enrichment of interventional trial populations.
Presently, the staging of NAFLD is largely dependent on interpretation of liver biopsy specimens, with the inherent challenges of procedural complications, cost, patient acceptability and sampling error. 8 Alternative approaches to biopsy have been sought across liver disease aetiologies and include serum markers of fibrosis such as the Fibrosis-4 score, NAFLD fibrosis score, Enhanced Liver Fibrosis (ELF) test (iQur Limited, London, UK) 9 and imaging technologies based on transient elastography 10 and magnetic resonance imaging (MRI). 11 Many of these non-invasive techniques have acquired a role in routine clinical practice. To date for example, National Institute for Health and Clinical Excellence guidance for NAFLD recommends ELF as a risk stratification tool, and in the National Institute for
Health and Clinical Excellence guidance on cirrhosis; transient elastography is recommended for staging of fibrosis.
12,13
As diagnostic tests evolve and clinical and trial strategies change, comparative evaluation of novel technologies is critically important for users. We sought to determine how a novel quantitative liver MRI technology performed in terms of utility and comparative effectiveness, in the assessment of a prospective cohort of patients with NAFLD having routine liver biopsy as standard of care. We subsequently used the data to assess the potential cost effectiveness of this technique to understand whether this added investigation would reduce the cost burden of liver biopsy.
Our study was an academic led, funded, and delivered evaluation of a proprietary algorithm -LiverMultisca (Perspectum Diagnostics Ltd. Oxford, UK), a multiparametric MRI technology used to quantify liver fat, iron and fibro-inflammatory injury by proton density fat fraction, T2* mapping and corrected T1 (cT1) 14 mapping respectively. T1 as a biomarker of hepatic fibrosis is confounded by hepatic siderosis. cT1 uses a measurement of iron content (T2*) and a patented algorithm to correct for this confounding. 11 cT1 of the liver has previously been reported to stage hepatic fibrosis in an unselected population of patients undergoing liver biopsy. 11 The proton density fat fraction measured using a modified Dixon sequence is a well-established and accurate technique for the assessment of hepatic fat content. [15] [16] [17] Iron concentration was estimated from T2* according to a previously determined model. 18 We report our comparative evaluation of the ability of this quantitative MRI technology to identify patients with hepatic steatosis, differentiate those with simple steatosis from those with NASH, grade disease activity and stage hepatic fibrosis. We demonstrate maximal utility in the ability of multiparametric MRI to distinguish between patients at low risk and those at high risk of progressive disease.
| METHODS

| Study participants
Our prospective study was undertaken at the Queen Elizabeth Exclusion criteria were: biopsy of a distinct focal lesion, inability to
give fully informed consent and any contraindication to MRI.
Healthy volunteers were recruited from staff and students at the University of Birmingham. Exclusion criteria were obesity (Body mass index (BMI) >30 kg/m 2 ), current or previous history of liver disease, significant medical comorbidity, family history of liver disease, excess alcohol intake or any contraindication to MRI. All participants gave written, informed consent and attended for a single study visit during which they underwent multiparametric MRI, transient elastography with FibroScan (Echosens, Paris, France), blood sampling and collection of clinical and demographic data. All study investigations were performed after a 4 hour fast. Patients undertook their study visit in the 2 weeks prior to liver biopsy and healthy volunteers did not undergo liver biopsy.
| Study investigations
All MRI scans were performed at 3.0 tesla on Siemens Verio MRI scanners (Siemens Healthcare GMBH, Erlangen, Germany). The MRI protocol does not require intravenous contrast and has been previously described. 11 In brief, the participant lies supine with 3-lead ECG for cardiac gating. A combination of body matrix and spine matrix coil elements was used to acquire data. Following localisers and shimming, the sequences include: shortened modified Look
Locker inversion (ShMOLLI) recovery sequence (T1 mapping), multigradient-echo sequence (T2* mapping), modified Dixon sequence and proton magnetic resonance spectroscopy with the Stimulated Echo Acquisition Mode sequence. All data were acquired during diastole with breath held in expiration to minimise movement artefact. Maps were acquired in a transverse plane through the liver hilum using the same slice position for each sequence. The voxel for magnetic resonance spectroscopy was placed in the right lobe of the liver avoiding biliary and vascular structures. Details of the MRI sequence parameters are contained in the supplementary material.
Due to an error in the MRI acquisition protocol, proton density fat fraction as measured by the Dixon sequence (PDFF-Dixon) could not be calculated for the first 12 data sets. At this point, the error was identified and corrected. PDFF-Dixon was calculated reliably for the remaining participants.
Transient elastography was performed by trained operators (PJE and NM) in accordance with manufacturer's guidelines and validated local clinical practice. 19 The decision on using the M probe or XL probe was made by the automated probe selection tool incorporated into the FibroScan machine. Examinations were regarded as 'possible' if at least 10 valid readings could be recorded and 'reliable' if they contained at least 10 valid readings and had interquartile range (IQR) to median ratio ≤30% (Boursier's criteria). 20 At the start of the study the Controlled Attenuation Parameter was not available on the FibroScan XL probe. Controlled Attenuation Parameter on the XL probe was enabled during study recruitment so was recorded if available in addition to median liver stiffness.
Blood samples were analysed routinely for markers of liver disease. Simple blood biomarker panels including aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, Fibrosis-4 (FIB-4) and NAFLD fibrosis score were calculated according to published formulae. 21, 22 Serum was also analysed to determine the enhanced liver fibrosis (ELF) score. MRI as an adjunct to transient elastography, and using multiparametric MRI alone. We repeated this analysis, using the data collected from our study, based on the risk stratification pathways detailed in Figure S1 . For each risk stratification pathway, failure rates of transient elastography and MRI were used as reported in the previous study 31 and we presumed the failure rate of ELF to be negligible at 0%. Using the prevalence of NAFLD in the previous study cohort patients. This was then subtracted from the total cost that would result from performing biopsies on all patients, to estimate the cost savings of each pathway. The resulting value was divided by the number of correct diagnoses, to estimate the cost per correct diagnosis, which could then be compared to the cost of a biopsy.
| MRI data analysis and iron correction
3 | RESULTS
| Patient demographics
Of 54 patients with NAFLD recruited into the study (whole study included 162 unselected liver biopsies) 50 had sufficient data for analysis. Three MRI data sets were unusable and 1 biopsy was judged too small for reliable fibrosis assessment and so these four patients were excluded. Seven healthy volunteers were recruited.
One healthy volunteer was subsequently excluded from analysis due to the discovery of abnormal liver biochemistry. The study flow chart is shown in Figure S2 . The characteristics of the 50 patients and six healthy volunteers are outlined in Table 1 . Comparisons between these groups found that the healthy volunteers were significantly younger (median 32 vs 54 years, P = .011), had significantly lower BMI and lower waist to hip ratio. Healthy volunteers were more likely to consume alcohol than patients, but there was no difference in the median consumption of drinkers and no patient or healthy volunteer drank alcohol to excess. 
| Differentiation between NASH and simple steatosis by cT1 measurement
Demographic characteristics and blood results presented in Table 3 showed no significant difference between patients with NASH and those with simple steatosis. cT1 showed a significant difference between simple steatosis and NASH and, although not validated for this purpose, liver stiffness and ELF also showed significant differences between patients with simple steatosis and those with NASH (Table 4) .
Whilst multiparametric MRI did differentiate between NASH and simple steatosis, the AUROC (95% CI) for cT1 0.69 (0.50-0.88) was inferior to ELF 0.87 (0.77-0.79) and liver stiffness 0.82 (0.70-0.94) (Figure 2 ).
| Grading of disease activity by cT1 measurement
In patients with NAFLD, semi-quantitative assessment of hepatocyte ballooning showed a statistically significant correlation with cT1, liver stiffness, and ELF. Lobular inflammation was significantly correlated with liver stiffness and ELF but not cT1. Overall assessment of disease activity (as defined by the total NAFLD activity score) showed significant correlation with cT1, liver stiffness and ELF. The strength of these correlations can be seen in Table 5 
| 635
Statistically significant differences were demonstrated between healthy volunteers and F2 fibrosis (P = .048) and F3 fibrosis (P = .003). However, cT1 showed no significant trend across the fibrosis stages (P = .068), with pair wise comparisons finding no evidence of significant differences between individual fibrosis stages in patients with NAFLD. As shown in Figure 5 , there was no evidence of significant correlation between cT1 and collagen proportionate area in patients with NAFLD (q = 0.142, P = .324).
In NAFLD patients, there was a significant association between T stiffness, ELF, AST:ALT ratio and NAFLD fibrosis score showed statistically significant differences between healthy volunteers, low risk patients and high risk patients as shown in Table 6 . The AUROC (95% CI) to differentiate the different groups is shown in Table 7 ,
T A B L E 5 Correlations between non-invasive biomarkers and the components of the NAFLD activity score showed a significant association with hepatocyte ballooning and total NAFLD activity score but not with lobular inflammation (n = 50). B. Liver stiffness showed a significant association with hepatocyte ballooning, lobular inflammation and total NAFLD activity score (n = 47). C. ELF score showed a significant association with hepatocyte ballooning and lobular inflammation but not total NAFLD activity score (n = 50) and confirmed effective utility of multiparametric MRI as well as liver stiffness and ELF to exclude liver disease, with cT1 having the highest AUROC for differentiation of NAFLD and healthy volunteers (0.93).
Taking common cut-off values for the three best performing tests, sensitivity, specificity, negative predictive value and positive predictive value for the diagnosis of high-risk patients were calculated and are shown in Table 8 . Importantly, negative predictive values, suggesting those patients for whom biopsy could potentially be avoided, were substantially higher for cT1 (80.0%-83.3%) compared to liver stiffness (39.1%-42.9%) and ELF (26.3%-57.1%).
| Cost analysis of non-invasive tests for the staging of NAFLD
The results of applying the sensitivity and specificity described in this study to the previously published decision tree model using our cohort of patients with NAFLD are provided in Table 9 The risk stratification pathways considered the use of each test individually and also the combination of transient elastography followed by multiparametric MRI. For example, the use of the "cT1 only" risk stratification pathway using a 875 ms cut-off was estimated to reduce the number of biopsies required by almost half (reduction of 458 per 1,000 patients). As a result, the estimated saving was £150,218 per 1000 patients, relative to the pathway in which biopsies are performed on all patients. All of the pathways considered were found to be potentially cost saving, relative to biopsy alone, with the exception of ELF at the lower cut-off of 7.7. In addition, those pathways that combined transient elastography and multiparametric MRI provided additional cost savings over multiparametric MRI alone. For example, the estimated cost per correct diagnosis was £554.26 using cT1 with a cut-off of 875 ms, which reduced to £307.92 in the pathway where this was preceded by liver stiffness (7.0 kPa cut-off).
| DISCUSSION
The global burden of NAFLD is increasing inexorably and validated non-invasive diagnostic tests are important for patients, clinicians Based on reliable scans only (n = 53). Data reported as mean AE SD, with P-values from one-way ANOVA or median (range), with P-values from Kruskal-Wallis tests, as applicable. Bold P-values are significant at P < .05.
Identifying those patients with NAFLD requires accurate detection of steatosis. In clinical practice, steatosis is typically assessed by visual grading of standard liver ultrasound images. 32 Although the sensitivity of ultrasound in detecting moderate and severe steatosis is good, there is wide interobserver and intraobserver variability. A single test to reliably exclude NAFLD would be of considerable value in clinical practice. In this study, multiparametric MRI showed a high degree of accuracy for differentiating between healthy T A B L E 7 cT1, liver stiffness and ELF and stratification of low and high risk patients 38 To date, the differentiation of simple steatosis and NASH has been reliant on liver biopsy. Liver biopsy has low patient acceptability due to its invasiveness and associated risk. Liver biopsy is also prone to sampling error and interobserver variation in histological assessment. These factors reduce the suitability and reliability of liver biopsy for disease stratification in NAFLD. Currently available methods to non-invasively differentiate NASH and simple steatosis are suboptimal. Conventional blood tests and imaging techniques have low accuracy for the differentiation of simple steatosis and NASH. 38 To determine the severity of disease, cT1 showed a highly significant, positive correlation with NAFLD activity score. The correlation between NAFLD activity score and cT1 was stronger than between NAFLD activity score and any other evaluated test, althought the authors acknowledge that these tests are not designed to assess disease activity. This indicates the potential utility of multiparametric Table 8 , with the rate of correct and incorrect outcomes being the sum of the true positives and true negatives (correct), or the false positives and false negatives (incorrect), respectively, for the pathway. Costs for each diagnostic pathway include all predicted test and biopsy costs for a cohort of 1000 patients. F I G U R E 6 Box plot showing the influence of overall disease activity (as assessed by NAFLD activity score) on cT1. In patients with low stage fibrosis there was significant difference in cT1 between those with NAFLD activity score <5 compared to those with a NAFLD activity score ≥5. This distinction had a trend towards significance in higher stage fibrosis. NAS: NAFLD activity score
MRI as a sensitive diagnostic tool to monitor changes in disease activity. A NAFLD activity score of ≥5 is frequently used as a criterion to enrich clinical trials with patients with more significant liver disease. The performance of cT1 to make this distinction was comparable to the other non-invasive markers evaluated in this study.
Staging of fibrosis in NAFLD has been clearly shown to predict clinical outcomes [5] [6] [7] and thus is an important part of the assessment of patients with NAFLD in clinical practice and for inclusion in current late stage clinical trials. In addition, both cT1 and ELF have also been reported to have utility in predicting clinical outcomes. 39, 40 In this cohort, cT1 did not predict fibrosis defined by either Kleiner stage or collagen proportionate area whereas the other non-invasive markers assessed in this study performed in line with published work. 41, 42 The lack of correlation between cT1 and fibrosis in this study was unexpected as previous work by Banerjee et al in unselected patients 11 and by Pavlides et al in patients with NAFLD 43 has shown a clear correlation between cT1 and fibrosis stage. It may be that our study is underpowered to detect this correlation, however, in our study, it appears that the influence of disease activity on cT1
has hampered the ability of cT1 to detect stage differences in fibrosis; larger studies are needed to explore this further. Figure 6 shows the heavy confounding of disease activity on fibrosis assessment in this cohort. When grouped by fibrosis stage, the only statistically significant difference in cT1 is between low and high NAFLD activity score in patients with early stage fibrosis. This identification of a group of patient with early stage fibrosis and less severe disease as graded by NAFLD activity score characterises a group of patients at low risk of progressive liver disease. As shown in Table 8 , cT1 had comparable sensitivity, specificity and positive predictive value to ELF and liver stiffness for the exclusion of significant disease (NASH or fibrosis ≥F1) but notably greater negative predictive value suggesting that multiparametric MRI can identify patients without significant liver disease with confidence. These patients would potentially not need further investigations.
Our study was prospective and enrolled unselected consecutive patients across two sites. The statistical power is limited by recruitment volume, which may have resulted in some of the more subtle associations between variables being missed. Despite this, our independently collected data confirms the opportunities for new non-invasive biomarkers in liver disease severity assessment.
Although liver biopsy remains the gold standard, as a comparator it has known limitations of sampling error and interobserver variation. 25, 44 However, in our study we demonstrated that semiquantitative histology scores correlated strongly with collagen proportionate area and other biomarkers performed as per previous publications.
In conclusion, multiparametric MRI with LiverMultiscan has the ability to identify patients with NAFLD and to quantify steatosis and 
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